Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview
- PMID: 10871732
- PMCID: PMC7091624
- DOI: 10.1038/sj.bmt.1702447
Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview
Abstract
Mucositis is an inevitable side-effect of the conditioning regimens used for haematopoietic stem cell transplantation. The condition is better referred to as mucosal barrier injury (MBI) since it is primarily the result of toxicity and is a complex and dynamic pathobiological process manifested not only in the mouth but also throughout the entire digestive tract. A model has been proposed for oral MBI and consists of four phases, namely inflammatory, epithelial, ulcerative and healing phases. A variety of factors are involved in causing and modulating MBI including the nature of the conditioning regimen, the elaboration of pro-inflammatory and other cytokines, translocation of the resident microflora and their products, for example, endotoxins across the mucosal barrier, exposure to antimicrobial agents and whether or not the haematopoietic stem cell graft is from a donor. Neutropenic typhlitis is the most severe gastrointestinal manifestation of MBI, but it also influences the occurrence of other major transplant-related complications including acute GVHD, veno-occlusive disease and systemic infections. The pathobiology, clinical counterparts and the means of measuring MBI are discussed together with potential approaches for prevention, amelioration and, perhaps, even cure. Bone Marrow Transplantation (2000) 25, 1269-1278.
Figures


References
-
- Berger AM, Kilroy TJ. Cancer; Principles and Practice of Oncology, 5th edn. 1997. Adverse effects of treatment; oral complications. In: DeVita VT, Hellman S, Rosenberg SA (eds) pp. 2714–2725.
-
- Schubert MM, Williams BE, Lloid ME. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer. 1992;69:2469–2477. - PubMed
-
- Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72:1612–1617. - PubMed
-
- Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol. 1998;34:63–71. - PubMed
-
- Donnelly JP, Muus P, Schattenberg A. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant. 1992;9:409–413. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical